Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial
Open Access
- 16 April 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in The Esophagus
- Vol. 46 (6), 724-735
- https://doi.org/10.1007/s00535-011-0397-7
Abstract
The efficacy of low-dose lansoprazole has not been established for the prevention of recurrent gastric or duodenal ulcers in those receiving long-term low-dose aspirin (LDA) for cardiovascular and cerebrovascular protection. This study sought to examine the efficacy of low-dose lansoprazole (15 mg once daily) for the secondary prevention of LDA-associated gastric or duodenal ulcers. Patients were randomized to receive lansoprazole 15 mg daily (n = 226) or gefarnate 50 mg twice daily (n = 235) for 12 months or longer in a prospective, multicenter, double-blind, randomized active-controlled trial, followed by a 6-month follow-up study with open-label lansoprazole treatment. The study utilized 94 sites in Japan and 461 Japanese patients with a history of gastric or duodenal ulcers who required long-term LDA therapy for cardiovascular and cerebrovascular disease. The primary endpoint was the development of gastric or duodenal ulcers. The cumulative incidence of gastric or duodenal ulcers on days 91, 181, and 361 from the start of the study was calculated by the Kaplan–Meier method as 1.5, 2.1, and 3.7%, respectively, in the lansoprazole group versus 15.2, 24.0, and 31.7%, respectively, in the gefarnate group. The risk of ulcer development was significantly (log-rank test, P < 0.001) lower in the lansoprazole group than in the gefarnate group, with the hazard ratio being 0.099 (95% confidence interval [CI] 0.042–0.230). Lansoprazole was superior to gefarnate in reducing the risk of gastric or duodenal ulcer recurrence in patients with a definite history of gastric or duodenal ulcers who required long-term LDA therapy.Keywords
This publication has 19 references indexed in Scilit:
- Changes in the prevalence of Helicobacter pylori infection and gastrointestinal diseases in the past 17 yearsJournal of Gastroenterology and Hepatology, 2010
- Efficacy of Esomeprazole (20 mg Once Daily) for Reducing the Risk of Gastroduodenal Ulcers Associated With Continuous Use of Low-Dose AspirinThe American Journal of Gastroenterology, 2008
- Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trialThe Lancet, 2008
- A clinical study of Japanese patients with ulcer induced by low‐dose aspirin and other non‐steroidal anti‐inflammatory drugsAlimentary Pharmacology & Therapeutics, 2005
- Lansoprazole for the Prevention of Recurrences of Ulcer Complications from Long-Term Low-Dose Aspirin UseThe New England Journal of Medicine, 2002
- Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradicationGut, 2000
- Major virulence factors, VacA and CagA, are commonly positive inHelicobacter pylori isolates in JapanGut, 1998
- Efficacy and safety of famotidine in the management of benign gastric ulcersThe American Journal of Medicine, 1986
- Therapeutic effect of pirenzepine dihydrochloride on gastric ulcer evaluated by a double-blind controlled clinical study. Phase III study.1982
- A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa.1981